首页 > 抗体蛋白 > 抗体
PE/Cyanine7 anti-mouse CD4 Antibody
产品名称:
PE/Cyanine7 anti-mouse CD4 Antibody
产品类别:
抗体
产品编号:
100527
产品应用:
100527
[价格]
规格 价格 库存
25µg ¥ 1232 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
BALB/c mouse thymocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 ?g per 106 cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4+ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4+ cells1, and immunohistochemistry of acetone-fixed frozen tissue sections2,3,11 and paraffin-embedded sections11. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF? Purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Additional Product Notes
BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
  2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
  4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
  5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
  7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
  8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
  9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
  10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
  11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
Product Citations
  1. Quispe Calla N, et al. 2016. Sci Rep. 6:37723. PubMed
  2. Xing J, et al. 2021. Cell Reports. 35(12):109205. PubMed
  3. Kaczanowska S, et al. 2021. Cell. 184(8):2033-2052.e21. PubMed
  4. Du C, et al. 2016. Nat Commun. 7: 11120. PubMed
  5. Nocera D, et al. 2016. J Immunol. 196: 2860 - 2869. PubMed
  6. Gravano D, et al. 2010. PLoS One. 5:e13528. PubMed
  7. Vanderleyden I, et al. 2020. Cell Rep. 30:611. PubMed
  8. Hastings AK, et al. 2019. iScience. 13:339. PubMed
  9. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  10. Gengenbacher M, et al. 2016. MBio. 7: 00679-16. PubMed
  11. Wang D, et al. 2018. Immunity. 48:659. PubMed
  12. Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed
  13. Blake SJ, et al. 2021. Cell Rep Med. 2:100464. PubMed
  14. Manivasagam S, et al. 2022. J Immunol. 208:1341. PubMed
  15. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  16. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  17. Choi JY, et al. 2020. Proc Natl Acad Sci U S A. 117:6042. PubMed
  18. Schaller M, et al. 2015. J Leukoc Biol. 98: 601 - 613. PubMed
  19. Bhattacharjee S, et al. 2019. Cell Rep. 28:231. PubMed
  20. Guo Q, et al. 2021. Front Cardiovasc Med. 8:633212. PubMed
  21. Waide ML, et al. 2020. Cell Rep. 33:108503. PubMed
  22. Si Y, et al. 2020. Sci Adv. 6:eaba0995. PubMed
  23. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  24. Thompson PJ et al. 2019. Cell metabolism. 29(5):1045-1060 . PubMed
  25. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  26. Blankenhaus B, et al. 2014. PLoS Pathog. 10:1003913. PubMed
  27. Kedage V, et al. 2022. MAbs. 14:2040083. PubMed
  28. Matsumura K, et al. 2016. J Immunol. 197: 3233 - 3244. PubMed
  29. Jassinskaja M, et al. 2021. Cell Reports. 34(12):108894. PubMed
  30. Miyazaki M et al. 2017. Immunity. 46(5):818-834 . PubMed
  31. Ly A, et al. 2020. Cell Reports. 29(8):2257-2269.e6.. PubMed
  32. JI B, et al. 2016. Cell Death Differ. 23:759-75. PubMed
  33. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
  34. Daniel CJ, et al. 2022. Mol Cancer Res. 20:1151. PubMed
  35. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  36. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  37. Imani J, et al. 2021. JCI Insight. 6:. PubMed
  38. Pishesha N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  39. Brandi P, et al. 2022. Cell Rep. 38:110184. PubMed
  40. Chen X, et al. 2021. Cell Rep. 37:109991. PubMed
  41. Carty S, et al. 2014. PLoS One. 9:106659. PubMed
  42. Macdougall CE et al. 2018. Cell metabolism. 27(3):588-601 . PubMed
  43. Martínez‐López M et al. 2019. Immunity. 50(2):446-461 . PubMed
  44. Liu B, et al. 2022. Mol Med Rep. 26:. PubMed
  45. Studniberg SI, et al. 2022. Mol Syst Biol. 18:e10824. PubMed
  46. Ballet R, et al. 2014. PLoS Pathog. 10:1004550. PubMed
  47. Xu X, et al. 2018. J Dermatol Sci. 91:134. PubMed
  48. Riding AM, et al. 2022. iScience. 25:104660. PubMed
  49. Mandal RK, et al. 2021. Cell Reports. 35(6):109094. PubMed
  50. Hirata SI, et al. 2020. Allergy. 75:1939. PubMed
  51. Frohner IE, et al. 2020. Cell Rep. 30:3171. PubMed
  52. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  53. Macagno M, et al. 2014. J Immunol. 192:5434. PubMed
  54. Laubreton D, et al. 2020. Viruses. 12:00. PubMed
  55. Di Lorenzo A, et al. 2022. Oncoimmunology. 11:2086752. PubMed
  56. Kim D, et al. 2020. Immunity. 53(3):581-596.e5. PubMed
  57. Yang X, et al. 2021. Bioact Mater. 3150:6. PubMed
  58. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  59. Wan X, Thomas J, Unanue E 2016. J Exp Med. 213: 967 - 978. PubMed
  60. Ryg-Cornejo V, et al. 2016. Cell Rep. 14:68-81. PubMed
  61. Chong WP, et al. 2020. Immunity. 53(2):384-397.e5.. PubMed
  62. Platteel ACM, et al. 2018. Front Immunol. 1.544444444. PubMed
  63. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  64. Guan D, et al. 2021. Cell Death Dis. 12:431. PubMed
  65. Lai NY, et al. 2020. Cell. 180:33:00. PubMed
  66. Hassan H, et al. 2011. Proc Natl Acad Sci U S A. 108:18330. PubMed
  67. Lau A, et al. 2022. Sci Adv. 8:eabm0142. PubMed
  68. Dietschmann A, et al. 2020. Eur J Immunol. 50:1044. PubMed
  69. C Khouili S, et al. 2020. Cell Rep. 33:108468. PubMed
  70. Campisi L, et al. 2016. Nat Immunol. 10.1038/ni.3512. PubMed
  71. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  72. Kubli SP, et al. 2019. Nat Commun. 10:2678. PubMed
  73. Okubo A, et al. 2021. Int J Mol Sci. 23:. PubMed
RRID
AB_312728 (BioLegend Cat. No. 100527) AB_312729 (BioLegend Cat. No. 100528)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线